IsoalloLCA-intervened regulatory T cell exosomes alleviate inflammatory bowel disease by inhibiting NF-κB-associated inflammation in intestinal epithelial cells
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.114501 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Simei Yue und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China. Hauptthemen laut MEDLINE: Exosomes, T-Lymphocytes, Regulatory, Intestinal Mucosa, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: Renmin Hospital of Wuhan University, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Regulatory T cells (Tregs) are the principal immune cells that exert anti-inflammatory effects within the organism. Their exosomes exhibit therapeutic efficacy across a broad spectrum of diseases owing to their high stability, low immunogenicity, and substantial penetration capacity. Recent research have indicated that isoallolithocholic acid (isoalloLCA), a metabolite associated with bile acid metabolism, may enhance Treg activity by upregulating forkhead box protein3 (Foxp3) expression. Hence, metabolite-based strategies for reinforcing Tregs may offer novel intervention options for treating related diseases. In this study, tumor necrosis factor (TNF)-α and dextran sulfate sodium (DSS) were employed to establish cellular and animal models of inflammatory bowel disease (IBD), further evaluating the therapeutic efficacy of isoalloLCA-intervened regulatory T cell exosomes (isoalloLCA-Exo) within this model. Our findings demonstrated that isoalloLCA-Exo effectively inhibit colitis progression in a murine model, as indicated by reduced inflammation, decreased apoptosis of intestinal epithelial cells, and improved intestinal barrier function. Furthermore, in vitro analyses elucidated the molecular mechanisms underlying the anti-inflammatory effects of isoalloLCA-Exo, revealing that the intervention effectively reversed TNF-α-induced inflammation and apoptosis in intestinal epithelial cells by modulating the NF-κB pathway. In conclusion, isoalloLCA-Exo can decelerate inflammatory bowel disease progression and suppress inflammatory response in intestinal epithelial cells by inhibiting NF-κB pathway. Notably, isoalloLCA-Exo exhibit superior efficacy to the traditional drug mesalazine and conventional treg exosome(NC-Exo). These findings have significant implications for optimizing Treg-derived exosome-based therapies for inflammation-related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Wuhan University Shenzhen Research Institute, Shenzhen, Guangdong 518000, China; Central Laboratory of Renmin Hospital of Wuhan U…
Förderung
- Renmin Hospital of Wuhan University
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Yue, S., Gong, L., Tan, Y., Zhang, X., & Liao, F. (2025). IsoalloLCA-intervened regulatory T cell exosomes alleviate inflammatory bowel disease by inhibiting NF-κB-associated inflammation in intestinal epithelial cells. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114501
Vancouver
Yue S, Gong L, Tan Y, Zhang X, Liao F. IsoalloLCA-intervened regulatory T cell exosomes alleviate inflammatory bowel disease by inhibiting NF-κB-associated inflammation in intestinal epithelial cells. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114501
BibTeX
@article{Yue2025,
author = {Yue, Simei and Gong, Lingjiao and Tan, Yulin and Zhang, Xiaodan and Liao, Fei},
title = {IsoalloLCA-intervened regulatory T cell exosomes alleviate inflammatory bowel disease by inhibiting NF-κB-associated inflammation in intestinal epithelial cells},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.114501}
}
EUVIMED